GHRP-2 10mg

Size:10mg
Contents: GHRP-6
Form: Lyophilized powder
Purity: >99%
SKU: P-GHRP6

FREE Shipping on $200+ orders

GHRP-6 Peptide

Growth hormone releasing hexapeptide, or GHRP-6, belongs to a group of synthetic peptides developed with the potential to stimulate the secretion and regulate growth hormone levels. Similar to most such peptides, GHRP-6 is an analog of the naturally occurring opioid peptide and neuromediator called met-enkephalin. Yet, researchers suggest it may lack the opioid activity generally associated with these enkephalins.⁽¹⁾ Instead, GHRP-6 appears to interact with the so-called growth hormone secretagogue receptors (GHS-Rs) which eventually turn out to be ghrelin receptors. Thus, the peptide may also be defined as growth hormone secretagogue (GHS). It is a small, low molecular weight, synthetic peptide, which has been researched for its potential in growth hormone stimulation.⁽²⁾

Initially, growth hormone releasing peptides (GHRP) were developed with the intention of mimicking the mechanism of action of growth hormone releasing hormones (GHRHs). When GHRH was first isolated in 1984, scientists hypothesized that these compounds might operate differently; with GHRPs exhibiting an apparent affinity to bind with ghrelin receptors.⁽³⁾ Ghrelin is also known as the hunger hormone, and it is naturally produced by the stomach when empty. Researchers suspected that GHRPs, like the endogenously found hormone ghrelin, may appear to govern action via hypothalamic stimulation and may have the potential to influence various functions, including metabolism and nutrient absorption.

Overview

Research was conducted to determine if GHRP-6 requires endogenous GHRH presence in order to exert its potential. In one study,⁽⁴⁾ the researchers evaluated the impact of GHRP-6 exposure following either GHRH antagonist or saline presence in the research models. Blood samples were collected incrementally for the next few hours and the concentrations of growth hormones was measured. Following the study, the researchers suggested that hGH levels were lower in models presented with GHRH antagonist. They posited further that endogenous GHRH may be necessary for GHRP-6 to exert potential action.

While the mechanism of GHRP-6 remains under study,⁽⁴⁾ further research studies have suggested that GHRPs may act by binding with two receptors, GHS-R1a, and CD36. In addition to hGH release, GHRP-6 also appears to have the potential to reduce cellular death through binding with CD36 receptors, possibly stimulating prosurvival cellular pathways.⁽²⁾ This remains under investigation.

Earlier it was hypothesized that GHRP-6 may work through a double mechanism, producing possible activities at the pituitary gland and hypothalamus. In a study to investigate this mechanism of action,⁽⁵⁾ two research model groups were evaluated, one group of hypothalamus-pituitary disconnection and one control model. Each subject was either presented GHRH, GHRP-6, or a combination of both. After presentation, the hGH levels were measured in all. In the control group, the highest levels of hGH were found in models given both GHRH and GHRP-6, followed by GHRP-6 models, and lastly the GHRH models. These results appeared to be converse in the research models of hypothalamic pituitary disconnection, with the least levels of HGH reported in those exposed to both GHRP-6 and GHRH. The GHRH subjects appeared to have the same levels of hGH as controls, whereas the hGH levels were reportedly reduced in models exposed to GHRP-6 alone. Two hypotheses were extended by the researchers from this study – first, GHRP-6 action may be induced primarily in the presence of GHRH and second, that GHRP-6 may act on hypothalamic pituitary axis in order to produce its potential.

Furthermore, researchers posited that GHRP-6 may potentially show an affinity toward CD36 receptors. These receptors are thought to fulfill various functions, such as possibly playing a part in lipid metabolism by acting as a scavenger receptor for lipids, aiding in their absorption, and possibly influencing immune responses by controlling phagocytosis and inflammation. The pathways involving CD36 might also have a role in the regulation of angiogenesis.⁽⁶⁾

Chemical Makeup

Molecular Formula: C₄₆H₅₆N₁₂O₆
Molecular Weight: 873.03 g/mol
Other Known Titles: Growth Hormone Releasing Peptide-6

Research and Clinical Studies

GHRP-6 Peptide and Hypothyroidism

Hypothyroidism is typically characterized by reduced levels of growth hormone secretion. The main aim of this study⁽⁷⁾ was to determine whether GHRP-6, a supposed hGH release-stimulating agent, might be used to mitigate hGH level reduction. Research models of hypothyroidism were evaluated following random exposure to three different concentrations of GHRH, and GHRP-6. Following the completion of the study, it was observed by the researchers that the models exposed to GHRP-6 alone and with combination of GHRP-6 and GHRH appeared to induce significantly higher levels of growth hormones than GHRH alone. The possible reasoning behind this is that GHRP-6 may differ from GHRH, with the potential as a functional antagonist of somatostatin at the pituitary level, which may be potentially why GHRP-6 may exert possibly increased action on hypothyroidism compared to GHR